Medigene's Drug Veregen® receives market approval in Canada
(Thomson Reuters ONE) -
Medigene AG /
Medigene's Drug Veregen® receives market approval in Canada
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 10 September 2013. Medigene AG (MDG, Frankfurt, Prime
Standard) announced today that its drug Veregen(®) for the treatment of genital
warts has obtained market approval in Canada. Market launch of Veregen(®) by
Medigene's partner Triton Pharma is scheduled to take place during the first
half of 2014.
Veregen(®) is already being marketed in the USA (by Fougera), in Germany,
Austria and Switzerland (by Abbott), in Spain (by Bial), in Serbia (by
Pharmanova) as well as in the Netherlands (by Will-Pharma) and approved in
further countries. The launch of Veregen(®) in several other countries is
expected until the end of 2013. Medigene has entered into numerous marketing
partnerships for Veregen(®) across Europe, Asia, and America, and is planning to
continue this global licensing strategy to further leverage the product's market
potential.
About Veregen(®): Veregen(®), a topical treatment for external genital or
perianal warts, contains a concentrate of catechins with a complex defined
composition extracted from green tea leaves. In its current treatment guidelines
for sexually transmitted diseases, the US Center for Disease Control and
Prevention recommends Sinecatechins 15% ointment (Veregen(®)) as a possible
option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment
(Veregen(®)) has been included in the current European guideline on the
treatment of genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
Triton Pharma Inc.: The Canadian Company Triton Pharma, founded in 2001,
specializes in the commercialization of prescription drugs in gynecology
(women's health), urology, and dermatology. With proprietary and licensed
products on the market, the company is successfully positioning itself as the
ideal partner for Companies wishing to establish their products in Canada.
Further information can be obtained at: www.tritonpharma.ca.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene was the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®), and is developing an
innovative vaccine technology. For more information, please visit
www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(®) is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
http://hugin.info/132073/R/1728101/577044.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1728101]
Unternehmensinformation / Kurzprofil:
Datum: 10.09.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 294883
Anzahl Zeichen: 4628
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 128 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's Drug Veregen® receives market approval in Canada"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
